A Phase Ii Study of Bibw 2992, a Novel Irreversible Dual Egfr and Her2 Tyrosine Kinase Inhibitor (Tki), in Patients with Adenocarcinoma of the Lung and Activating Egfr Mutations after Failure of One Line of Chemotherapy (Lux-Lung 2)
Resource
JOURNAL OF CLINICAL ONCOLOGY v.27 n.15 SUPPL. S pp.8013
Journal
JOURNAL OF CLINICAL ONCOLOGY
Journal Volume
v.27
Journal Issue
n.15
Pages
801-3
Date Issued
2009
Date
2009
Author(s)
YANG, CHIH-HSIN